Li-Fraumeni syndrome is a rare hereditary disease characterized by an increased risk of developing multiple malignant neoplasms at an early age. The basis of the pathology is a mutation of the TP53 gene, which plays a key role in the regulation of the cell cycle and apoptosis. The clinical picture of the disease is characterized by the development of various types of cancer, such as soft tissue and bone sarcomas, brain tumors, adenocarcinoma of the mammary gland and adrenal glands, as well as other oncological diseases that occur at a young age. The syndrome was first described in 1969 by American scientists Frederick Li and Joseph Fraumeni.
History of the disease and interesting historical facts
In the late 1960s, American researchers Frederick Lee and Joseph Fraumeni conducted a series of observations of families with an unusually high incidence of various cancers in young patients. Their pioneering work, “A familial syndrome of sarcoma and other neoplasms,” published in the Annals of Internal Medicine in 1969, laid the foundation for our current understanding of the syndrome. Interestingly, the scientists initially observed five families with a characteristic clinical picture, where the survival rate after the initial diagnosis was about 57%, which is significantly higher than for sporadic forms of cancer. “This observation became the starting point for understanding the role of hereditary factors in carcinogenesis,” says Dr. Michael Thain, an expert in hereditary cancer syndromes.
Epidemiology
According to international hereditary cancer registries, the incidence of Li-Fraumeni syndrome is approximately 1 case per 5,000-20,000 population. However, experts believe that the actual prevalence may be higher due to insufficient diagnostics. In the structure of hereditary oncological syndromes, this diagnosis accounts for approximately 1-2% cases. A feature of epidemiology is the pronounced phenomenon of genetic anticipation - earlier manifestation of the disease and severe course in subsequent generations. According to studies, the median age of the first diagnosis is:
- 28 years for carriers of germline TP53 mutations
- 42 years for familial cases without confirmed mutation
- 60 years for sporadic cancers
Genetic predisposition to this disease
The main cause of the syndrome is the presence of germline mutations in the TP53 gene, located on the short arm of chromosome 17 (17p13.1). This gene encodes the p53 protein, an important tumor suppressor known as the "guardian of the genome." Mutations can be of various types:
- Missense mutations (70-80% cases)
- Nonsense mutations (10-15%)
- Reading frame shift (5-10%)
- Splicing mutations (less than 5%)
It is important to note that the penetrance of the TP53 mutation is extremely high: up to 90% carriers of the mutant gene develop at least one malignant neoplasm by the age of 60.
Risk factors for the development of this disease
In addition to genetic predisposition, there are additional factors that contribute to the implementation of TP53 mutation in the clinical picture:
- Ionizing radiation - increases the risk of secondary tumors by 3-4 times
- Chemotherapeutic drugs, especially alkylating agents
- Chronic inflammation and immunodeficiency states
- Smoking and alcohol abuse double the risk of developing primary tumors
- Constant exposure to UV radiation
A 2018 study showed that combined exposure to multiple risk factors exponentially increases the likelihood of developing cancer in TP53 mutation carriers.
Diagnosis of this disease
Key elements of diagnosis include a comprehensive assessment of clinical presentation and laboratory data. The University of Chicago core diagnostic criteria include:
- Cancer in a patient under 46 years of age
- Presence of sarcoma in a patient under 46 years of age with a first-degree relative with any type of cancer under 46 years of age
- The presence of two or more primary tumors in one patient
- Family history of multiple tumors
Laboratory diagnostics include TP54 gene sequencing using NGS, MLPA analysis, and functional testing of the p53 protein. Radiological examination methods (MRI, CT) are used to screen for possible tumor foci.
Treatment
The therapeutic strategy for Li-Fraumeni syndrome requires an individual approach, taking into account the type of tumor and the general condition of the patient. General principles of treatment include:
- Surgical removal of primary tumors with wide resection margins
- Minimizing the use of radiotherapy due to the risk of secondary tumors
- Careful selection of chemotherapeutic drugs taking into account the risk of mutagenesis
- Regular oncological monitoring every 3-6 months
Modern approaches include the use of targeted therapy and immunotherapy, which show encouraging results with minimal risk of secondary effects.
List of drugs used to treat this disease
The main groups of drugs used in the treatment of tumors in patients with Li-Fraumeni syndrome:
- Anthracycline antibiotics (doxorubicin, epirubicin)
- Taxanes (paclitaxel, docetaxel)
- Alkylating agents (cyclophosphamide, ifosfamide)
- Platinum-containing drugs (carboplatin, oxaliplatin)
- PARP inhibitors (olaparib, niraparib)
When choosing a chemotherapy regimen, special attention is paid to minimizing the mutagenic effect of drugs.
Disease monitoring
Regular monitoring includes a comprehensive examination every 3-6 months using the following methods:
- Clinical examination and anamnesis
- Laboratory tests of blood and urine
- Ultrasound of abdominal organs
- MRI of the brain and whole body
- Mammography/MRI of the mammary glands in women
The prognosis depends on the timeliness of diagnosis and the adequacy of treatment. Five-year survival with regular monitoring is 70-75%.
Age-related features of the disease
Clinical manifestations of the syndrome vary depending on the age group:
- Childhood (0-14 years): soft tissue and bone sarcomas predominate
- Adolescence (15-25 years): CNS tumors and adenocarcinomas are more common
- Young age (26-45 years): breast and thyroid cancers predominate
- Over 45 years: the frequency of carcinomas of various localizations increases
It is important to note that the earlier the first tumor appears, the higher the risk of developing multiple neoplasms.
Questions and Answers
- How often should you be tested for Li-Fraumeni syndrome? A quarterly examination is recommended, including a clinical examination, laboratory tests and instrumental research methods.
- Is it possible to prevent the development of tumors in this syndrome? Complete prevention is impossible, but regular monitoring allows for early detection of tumors and increased treatment effectiveness.
- How does pregnancy affect the course of the disease? Pregnancy does not have a direct effect on the course of the syndrome, but requires special monitoring due to the increased risk of developing breast tumors.
Advice from Dr. Oleg Korzhikov
Patients often ask how to properly organize a monitoring system. I recommend creating a personal medical passport where all examinations and consultations will be recorded. How often should children of mutation carriers be tested? Regular examinations should begin at the age of 5. It is especially important to explain to children who have reached adolescence the need to maintain a healthy lifestyle and give up bad habits. If any suspicious symptoms appear, you should immediately contact a doctor, even if a routine examination has recently been carried out.
